was shown to lack carbohydrate-binding activity, but is essential for the full biological activity of gal-3 [5] . Furthermore, the N-terminal domain has been implicated in the secretion of gal-3 [6] . The C-terminal domain includes a sugar-binding site known to be blocked by lactose [5, 7] . Galectins are expressed by a variety of cell types and are present both intracellularly and extracellularly in a large number of tissues and cell types such as epithelial cells, fibroblasts, keratinocytes, osteoclasts, Langerhans cells, dendritic cells, monocytes and macrophages [8] [9] [10] [11] [12] .
The function of gal-3 self is pleiotropic including cell proliferation, adhesion and survival [13] [14] [15] [16] . Galectins can modulate processes such as apoptosis, cytokine secretion, cell adhesion and migration [17] and are implicated in the regulation, activation, differentiation and survival of T-cells, playing critical roles in the modulation of chronic inflammatory disorders such as IBDs and other autoimmune diseases [18, 19] .
Gal-3 itself protects against the formation of reactive oxygen products [20] . Gal-3-transfected T-cells showed higher and faster growth rates compared to controls. It plays a role in wound healing and accelerating re-epithelialization [21] . Gal-3-deficient mice developed less inflammatory cell infiltrates in the peritoneal cavity after thioglycollate instillation compared to control mice [22] .
These known functions and our observation that gal-3 is a major activator of CLPF secreted by CECs is promising to further investigate its role in the intestinal immune system and the pathophysiology of IBD.
So far the potential involvement of gal-3 in IBD pathophysiology has not been investigated into greater detail. We further investigated the influence of gal-3 on the intestinal immune functions under physiologic conditions and its potential role in IBD.
Materials and Methods

CLPF Stimulation
Human CLPF of healthy controls (n = 3-5) were isolated and cultured as described previously [1] . Mucosa from surgical specimens was cut into 1-mm pieces, whereas biopsy specimens were used directly for the isolation of CLPF. Epithelial cells were separated in Hank's balanced salt solution without Ca 2+ and Mg
2+
(PAA Laboratories GmbH, Linz, Austria) with 2 m M EDTA (Sigma, Deisenhofen, Germany). The remaining tissue was rinsed and digested for 30 min at 37 ° C with 1 mg/ml collagenase 1 (Sigma), 0 · 3 mg/ml DNase I (Boehringer Ingelheim, Ingelheim, Germany) and 2 mg/ml hyaluronidase (Sigma) in PBS (Gibco, Karlsruhe, Germany). Isolated cells were cultured in 25 cm 2 cell culture flasks (Costar, Bodenheim, Germany) with Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS, penicillin (PAA Laboratories), streptomycin 10 mg/ml (PAA Laboratories), ciprofloxacin 2 mg/ml (Bayer, Leverkusen, Germany), gentamycin 50 mg/ml (PAA Laboratories) and amphotericin B 1 mg/ml (Biochrom, Berlin, Germany). Non-adherent cells were removed by subsequent changes of medium. The remaining cell culture contained CLPF and was used between passages 3 and 8. The study was approved by the University of Regensburg Ethics Committee.
Galectins
Recombinant human gal-1 and gal-2 were purchased by R&D Systems, Wiesbaden, Germany.
Recombinant Gal-3. HT-29 cells were obtained from the European Collection of Cell Culture and cultured in DMEM (PAA Laboratories) supplemented with 10% FCS (Pan Biotech, Aidenbach, Germany), 1% sodium pyruvate (PAA Laboratories), 1% non-essential amino acids (PAA Laboratories) and 1% penicillin/ streptomycin under standard tissue culture conditions. Cells were cultured at 37 ° C in a 10% CO 2 atmosphere. Gal-3 was generated from HT-29 cells, and recombinant gal-3 was produced using the pET-vector systems followed by avidin chromatography purification (primer 5 ′ -CGGATCCAATGGCAGACAATTTTTC-3 ′ and 5 ′ -CCAAGCTTTTTATATCATGGTATATGAAGC-3 ′ ).
Enzyme-Linked Immunosorbent Assay IL-8 ELISA was performed according to the manufacturer's protocol (Biozol, Echingen, Germany).
Mice
Female BALB/c mice weighing 20-22 g (Charles River, Sulzfeld, Germany) were used for the experiments and housed in a conventional facility. Animal studies were approved by the review board of the regional authority ('Regierung der Oberpfalz').
Acute and Chronic Colitis
Dextran sodium sulfate (DSS) was purchased from ICN (Mr 37,000-50,000, Eschwege, Germany). The induction of acute colitis was achieved by administering 3% DSS in the drinking water ad libitum for 7 days. For induction of chronic colitis, BALB/c mice received 4 cycles of DSS treatment. Each cycle consisted of 3% DSS in drinking water for 7 days, followed by a 10-day interval with normal drinking water. In contrast to the self-limited inflammation in acute DSS colitis, which is induced by only 1 cycle of DSS feeding, chronic DSS-induced colitis is characterized by a self-perpetuating chronic inflammation, which lasts for several months. Four weeks after the induction phase, as well as in acute colitis, mice were treated with gal-3 in different concentrations dissolved in 100 μl PBS or PBS alone (100 μl, control) intraperitoneally (i.p.) daily for 5 days or day 3 to day 7. Mice used for experiments were age matched and had received DSS treatment simultaneously.
Measurement of Myeloperoxidase Activity
Colonic myeloperoxidase (MPO) activity was determined using a modified standard method. Briefly, colonic tissue was homogenized in 1 ml of 50 mmol/l potassium phosphate buffer of pH 6.0 containing 0.5% (w/v) hexadecyltrimethylammonium hydroxide, and it centrifuged at 20,000 g at 4 ° C for 20 min. Supernatant (10 μl) was transferred into the phosphate buffer of pH 6.0 containing 0.17 mg/ml 3,3 ′ -dimethoxybenzidine and 0.0005% H 2 O 2 . MPO activity of the supernatant was determined by measuring the H 2 O 2 -dependent oxidation of 3,3 ′ -dimethoxybenzidine and expressed as units per gram of total protein. Total protein content of the samples was analyzed using a bicinchoninic acid protein assay kit (Sigma, Germany).
Assessment of Histological Score
The distal third of the colon was removed and used for histological analysis as described before [23] . Cross-sections of the colon were fixed in 10% buffered formalin and stained with hematoxylin-eosin. To quantify the histological damage in intestinal tissue, a previously described scoring system was applied [24] . Histological analysis was performed by 2 investigators in a blinded fashion.
Polymerase Chain Reaction cDNA were synthesized from 1 μg total RNA using 2. 
Lymph Node Preparation
Mesenteric lymph nodes (MLNs; pooled from each group of mice) were collected under sterile conditions in cold cell culture medium (RPMI 1640, 10% FCS, 100 U/ml penicillin and 100 μg/ ml streptomycin from GIBCO-BRL (Eggenstein, Germany) and 3 × 10 -5 M 2-mercaptoethanol (Sigma, Deisenhofen, Germany)). Lymph nodes were mechanically disrupted and filtered through a cell strainer (70 μm). Cells (2 × 10 5 /well) were incubated in 200 μl culture medium for 24 h, and spontaneous cytokine secretion into the supernatants was measured by ELISA (all from Endogene, Woburne, Mass., USA), using 4 wells per condition.
Statistics
Statistical analysis was performed using the Mann-Whitney rank sum test or one-way analysis of variance with Bonferroni correction for more than 2 groups. Measured values are expressed as median ± 5th/95th percentile. Statistically significant differences were accepted when p value was less than 0.05.
Results
IL-10 and IL-4 Reduce Gal-3-Induced IL-8 Secretion While TGF-β1 Increases Gal-3-Induced IL-8
To evaluate if further proteins are additionally involved in the previously described pro-inflammatory effect of gal-3 in vitro, we performed co-incubation studies of gal-3 with different pro-and anti-inflammatory cytokines and other galectins.
CLPF of healthy controls were incubated with gal-3 ± gal-1 (10 μg/ml) or gal-2 (10 μg/ml) and pro-and antiinflammatory cytokines (TGF-β1 (1 ng/ml), IFNγ (1 ng/ ml), IL-4 (10 ng/ml) and IL-10 (5 ng/ml)) in different concentrations for 24 h. Subsequently, IL-8 secretion as a readout for cell activation was quantified in the supernatants of the cells by ELISA ( fig. 1 ). Data are given relatively for stimulation with gal-3 alone.
As demonstrated [1] , gal-3 dose-dependently induced IL-8 secretion of CLPF. Co-incubation of gal-3 and gal-1 resulted in a concentration-dependent increase of IL-8 secretion ( fig. 1 ; no statistical significance), while gal-2 did not further increase gal-3-induced IL-8 secretion (data not shown). Stimulation with gal-3 and TGF-β1 had a synergistic effect on IL-8 secretion reaching statistical significance compared to gal-3 alone ( fig. 1 ; p < 0.04), while IFNγ had no significant additional effect on proinflammatory IL-8 secretion of gal-3 ( fig. 1 ) . However, IL-10 (p < 0.05) and IL-4 (p < 0.002) co-incubation with gal-3 significantly reduced IL-8 secretion by CLPF ( fig. 1 ) .
While the IL-8 inducing effect of gal-3 was augmented by cytokines such as TGF-β1 -a protein with pleiotropic 
Gal-3 Reduces Inflammation in Acute DSS-Induced Colitis in Mice
To further assess the effect of gal-3 in intestinal inflammation in vivo, we investigated the role of gal-3 in a mouse model of acute DSS-induced colitis. Gal-3 was applied i.p. in different concentrations (100, 50, 10, 1 and 0.1 μg/ml), while PBS i.p. was used as control. Reduction of the colon length caused by the infiltration of inflammatory cells is a well-known feature of DSS colitis [25] . Colon length was significantly increased in gal-3-treated mice compared to controls in a concentration-dependent manner ( fig. 2 a) . Mice were monitored for clinical signs of colitis and differences in the course of weight loss. Weight loss was lower in gal-3-treated mice (gal-3 1 μg/ Gal-3 reduces inflammation in acute colitis. a Gal-3 treated mice showed increased colon length (p < 0.009 with gal-3 50 μg/ml). b Gal-3 treated mice had less weight loss compared to control mice (statistical significance at day 7 for gal-3 1 μg/ ml and gal-3 0.1 μg/ml treated mice compared to control, p < 0.001 for both groups). 49 ml, p < 0.001 and gal-3 0.1 g/ml, p < 0.001; fig. 2 b) . Histologic analysis demonstrated significantly less inflammation and less tissue damage in the gal-3 groups ( fig. 2 c) . Gal-3-treated mice had a lower score of inflammation compared to controls reaching statistical significance (100 μg/ml: 0.005; 50 μg/ml: 0.005). In contrast, MPO activity revealed only statistical significance in animals treated with gal-3 0.1 μg/ml (p < 0.001), however, showing decreased levels in the treatment groups, but with no statistical significance (data not shown). To evaluate whether amelioration of intestinal inflammation in gal-3-treated animals was accompanied by modulation of cytokine secretion, we compared cytokine production of MLN. Cytokine concentrations were measured in the supernatants of MLN pooled from controls and gal-3-treated mice. IL-6 secretion was inversely correlated to gal-3 concentration applied ( fig. 2 d) . No significant differences were seen for the secretion of TNFα, IL-4 and IL-10 in controls and gal-3-treated animals (data not shown). In contrast to our in vitro findings, gal-3 was able to modulate inflammation and improve acute DSS colitis by reducing pro-inflammatory cytokine secretion and inflammation in the colon by modulating IL-6 secretion. To further clarify the role of gal-3 in vivo, we investigated the impact of gal-3 in a chronic model of DSS-induced colitis.
Gal-3 Improves Inflammation in Chronic DSS-Induced Colitis in Mice
In the chronic DSS colitis model, gal-3-treated mice displayed a concentration-dependent increase of colon length (with a statistical significance peak in the group receiving 10 μg/ml gal-3) indicating less inflammation in gal-3-treated animals ( fig. 3 a) . MPO activity showed a clear decrease in the treatment groups not reaching statistical significance (data not shown). Histologic analysis revealed that DSS-induced inflammation was reduced in gal-3-treated animals compared to the control group in a concentration-dependent manner ( fig. 3 b; gal-3 100 μg/ ml, p < 0.001 and gal-3 50 μg/ml, p < 0.001).
Pro-inflammatory cytokine secretion (IL-6) was suppressed in gal-3-treated mice in a concentration-dependent manner with lowest IL-6 levels in mice treated with highest gal-3 concentrations (100 μg/ml; fig. 3 c) . No significant differences were seen for the secretion of IL-10, IL-4 and TNFα (data not shown). Similar to the acute colitis model, gal-3 was also able to reduce inflammation and improve histology scores in a chronic model of DSS colitis.
Discussion
In this study, we were able to extend previous findings as our data show a crucial role for gal-3 in intestinal inflammation in vitro and in vivo. Our results show an in- The induction of IL-8 secretion by gal-3 was increased upon co-incubation with TGF-β1, while IL-4 and IL-10 were able to antagonize the gal-3 effect on IL-8 secretion.
Using the DSS model of colitis, we were able to show a protective role of gal-3 in both acute and chronic inflammation. Significant reduced signs of inflammation were detected in the acute DSS model of colitis with increased colon length as a sign of lesser inflammation in gal-3-treated mice. Furthermore, gal-3 treatment improved colitis in the chronic DSS model. Gal-3 has extensively been studied in various kinds of inflammation with con- trary findings so far. In several studies, it was demonstrated that gal-3 might act as chemoattractant for dendritic cells or macrophages or can have an impact on the proliferation of activated T lymphocytes [26, 27] . Contrary to that, in fungal infections, gal-3 was shown to have a protective role [28] . In another model of infection, gal-3 was protective by a negative regulation of IL-17A responses through inhibition of IL-23/IL-17-axis cytokine production by dendritic cells [29] . Gal-3 was shown to have an inhibitory effect on monocyte migration and apoptosis [30] . However, infection with C. rodentium was only a minor effect in gal-3 null mice with delayed T-cell, macrophage and dendritic cells infiltration in the intestinal mucosa [31] . Our findings indicate a clear protective role of gal-3 with significant reduction of intestinal inflammation in a model of colitis.
Gal-3 seems to be protective in vivo by modulating IL-6 secretion. IL-6 is involved in a different kind of inflammation and in the regulation of the humoral immune system. In a mouse model, IL-6 has been shown to be a key player in TH1-mediated colitis while antagonizing IL-6 significantly improved colitis [32] . In humans, tocilizumab, a humanized anti-IL-6 receptor antibody, is already approved in the therapy of rheumatoid arthritis [33] and other autoimmune diseases [34] . A pilot study with tocilizumab in patients with CD has already indicated good tolerance, improved disease activity and effectiveness [35] , and tocilizumab is expected to be approved in the therapy of CD with newer data in the near future. These data and our findings indicate a central role for IL-6 in inflammation in IBD while targeting or suppression of this interleukin results in improved colitis.
Our observation is in agreement with previous findings in humans showing that gal-3 was reduced in active colitis while being elevated in patients with no clinical manifestations confirming a protective role of gal-3 in intestinal inflammation [36] . In active CD, gal-3 expression is decreased in the inflamed epithelium [37] . Gal-3 expression could be reduced by TNF incubation in the colonic adenocarcinoma cell line HCT-8 [37] . TNF certainly is an important mediator of IBD-associated inflammation. However, in CLPF, we found a synergistic effect of TNF α and gal-3. Other galectins such as gal-2 have been shown to induce T-cell apoptosis or modulate monocyte or macrophage functions [30, 38] . In experimental colitis, gal-2 was shown to be able to improve acute and chronic colitis showing a clear role of galectins in inflammation and modulation of the immune system [39] .
A substantially higher percentage of sera from CD patients contained anti-gal-3 IgG autoantibodies than from those with ulcerative colitis and healthy controls. In CD patients, the titer of autoantibodies negatively correlated with disease activity [40] . This result was confirmed recently and gal-3 was shown to modulate T-cell function in IBDs [41] . Beside, in human dendritic cells, gal-3 is capable of inhibiting T-cell activation. Knock down of gal-3 in dendritic cells was followed by increased IFNγ and reduced IL-10 expression [42] . Furthermore, gal-3 is able to influence TH17, a key player in tissue inflammation, by modulating cytokine secretion of dendritic cells [43] . Our study now provides evidence that gal-3 is able to modulate and improve colitis. Gal-3 showed a suppression of IL-6, indicating a TH1-mediated suppression of inflammation in this model of colitis. These findings are in accordance with published data where gal-3 was capable to suppress T-cell responses [44] .
To use a DSS model of colitis is widely accepted due to its simplicity and its similarity to human disease. However, a chemical induced model of colitis can never completely reflect the complexity of human disease, and the inherent differences between mice and humans need to be kept in mind. Therefore, further analysis of gal-3 in humans is warranted. Besides, the role and impact of gal-3 in other animal models of colitis need to be elucidated, since it is well known that they all use a different approach to inflammation (e.g. gene knockout, transgenic, chemical, adoptive transfer and spontaneous). These models will be helpful to further clarify the role of gal-3 in inflammation and to give a more detailed inside in the exact pathways used by gal-3 and to confirm our findings of a more TH1-balanced modulation of inflammation [45] .
In summary, we have demonstrated an in vivo model of acute and chronic colitis with a clear protective and key role of gal-3 and significant amelioration of intestinal inflammation. We could demonstrate that the gal-3 effect is mediated via modulation of IL-6.
Further investigations of gal-3 are warranted to underline the key role of gal-3 in inflammation and epithelial stabilization, to further characterize the subset of T-cells responsible for the protective effect of gal-3 and its potential role in IBDs.
